Publications by authors named "Peter Hellemans"

Claim this Profile
C
Clinical Pharmacokinetic Assessment of Lazertinib in Healthy Adult Participants: Effects of GSTM1 Genotype.
Jaydeep Mehta, Chuck Thompson, Ellen Scheers, Laurent Leclercq, Seong Bok Jang, Peter Hellemans

Clin Drug Investig· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Carbamazepine on the Pharmacokinetics of Erdafitinib in Healthy Participants.
Pharavee Jaiprasart, Peter Hellemans, Juhui James Jiao, Anne-Gaëlle Dosne, Marc De Meulder

Clin Pharmacol Drug Dev· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation.
Alex Yu, Anasuya Hazra, James Juhui Jiao, Peter Hellemans, Anna Mitselos

Clin Pharmacokinet· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors.
Victor Moreno, Ruth Perets, Tamar Peretz-Yablonski, Nele Fourneau, Suzette Girgis, Peter Hellemans

Invest New Drugs· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study.
Hareth Nahi, Saad Z Usmani, Maria-Victoria Mateos, Niels W C J van de Donk, Albert Oriol, Peter Hellemans

Leuk Lymphoma· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO).
Jesus San-Miguel, Saad Z Usmani, Maria-Victoria Mateos, Niels W C J van de Donk, Jonathan L Kaufman, Peter Hellemans

Haematologica· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6.
Jan de Jong, Anna Mitselos, Wojciech Jurczak, Raul Cordoba, Carlos Panizo, Peter Hellemans

Pharmacol Res Perspect· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer.
Ignacio Duran, Joan Carles, Iurie Bulat, Peter Hellemans, Anna Mitselos

Clin Pharmacokinet· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study.
Edwin M Posadas, Kim N Chi, Ronald de Wit, Maja J A de Jonge, Gerhardt Attard, Peter Hellemans

Clin Cancer Res· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study.
Italo Poggesi, Lilian Y Li, James Jiao, Peter Hellemans, Freya Rasschaert

Eur J Drug Metab Pharmacokinet· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.
Saad Z Usmani, Hareth Nahi, Maria-Victoria Mateos, Niels W C J van de Donk, Ajai Chari, Peter Hellemans

Blood· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies.
Jan de Jong, Peter Hellemans, Severijn De Wilde, Daniel Patricia, Tara Masterson

Leuk Lymphoma· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer.
Bodine P S I Belderbos, Ronald de Wit, Caly Chien, Anna Mitselos, Peter Hellemans

Cancer Chemother Pharmacol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pH-altering agent omeprazole affects rate but not the extent of ibrutinib exposure.
Jan de Jong, Nahor Haddish-Berhane, Peter Hellemans, James Jiao, Juthamas Sukbuntherng

Cancer Chemother Pharmacol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study.
Jan de Jong, Peter Hellemans, James Juhui Jiao, Yuhan Huang, Sofie Mesens

Cancer Chemother Pharmacol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study.
Jan de Jong, Peter Hellemans, James Juhui Jiao, Yuhan Huang, Sofie Mesens

Cancer Chemother Pharmacol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment.
Jan de Jong, Donna Skee, Peter Hellemans, James Jiao, Ronald de Vries

Leuk Lymphoma· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma.
Philippe Moreau, Thierry Facon, Cyrille Touzeau, Lotfi Benboubker, Martine Delain, Peter Hellemans

Leuk Lymphoma· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults.
Ronald de Vries, Johan W Smit, Peter Hellemans, James Jiao, Joseph Murphy

Br J Clin Pharmacol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants.
Jan de Jong, Donna Skee, Joe Murphy, Juthamas Sukbuntherng, Peter Hellemans

Pharmacol Res Perspect· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia.
Jan de Jong, Juthamas Sukbuntherng, Donna Skee, Joe Murphy, Susan O'Brien, Peter Hellemans

Cancer Chemother Pharmacol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation.
Martijn P Lolkema, Hilde H Bohets, Hendrik-Tobias Arkenau, Ann Lampo, Erio Barale, Peter Hellemans

Clin Cancer Res· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Anas Younes, Catherine Thieblemont, Franck Morschhauser, Ian Flinn, Jonathan W Friedberg, Peter Hellemans

Lancet Oncol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors.
Balaji Venugopal, Richard Baird, Rebecca S Kristeleit, Ruth Plummer, Richard Cowan, Peter Hellemans

Clin Cancer Res· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis